Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 1.68 is 51% below its 5-year average of 3.44, near the low end of its 5-year range (1.68–18.54).
As of the fiscal period ended Tuesday, June 30, 2026. 30.33% below its 12-month average of 2.42.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.68.
QUICK RATIO (ACID-TEST)
1.68
QUICK RATIO (ACID-TEST) AVG TTM
2.42
QUICK RATIO (ACID-TEST) AVG 3Y
2.80
QUICK RATIO (ACID-TEST) AVG 5Y
3.44
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.33%
CURRENT VS 3Y AVG
-39.82%
CURRENT VS 5Y AVG
-51.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 795 covered companies
CURRENT VS SECTOR MEDIAN
-48.68%
vs the sector median at left
Nuvectis Pharma, Inc.
Market Cap
$539.62M
Quick Ratio (Acid-Test)
1.68
TTM Avg
2.42
3Y Avg
2.80
5Y Avg
3.44
Market Cap
$537.71M
Quick Ratio (Acid-Test)
3.46
TTM Avg
4.63
3Y Avg
6.00
5Y Avg
6.13
Market Cap
$537.59M
Quick Ratio (Acid-Test)
1.87
TTM Avg
2.92
3Y Avg
5.55
5Y Avg
6.22
Market Cap
$541.49M
Quick Ratio (Acid-Test)
5.42
TTM Avg
12.18
3Y Avg
12.18
5Y Avg
12.18
Market Cap
$536.81M
Quick Ratio (Acid-Test)
8.95
TTM Avg
10.43
3Y Avg
5.97
5Y Avg
5.34
Market Cap
$543.14M
Quick Ratio (Acid-Test)
27.59
TTM Avg
10.29
3Y Avg
10.12
5Y Avg
12.12
Market Cap
$535.96M
Quick Ratio (Acid-Test)
8.36
TTM Avg
10.03
3Y Avg
20.35
5Y Avg
14.11
Market Cap
$525.68M
Quick Ratio (Acid-Test)
33.56
TTM Avg
31.41
3Y Avg
17.80
5Y Avg
16.41
Market Cap
$525.57M
Quick Ratio (Acid-Test)
25.13
TTM Avg
6.17
3Y Avg
7.34
5Y Avg
19.91
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $539.62M | 1.68 | 2.42 | 2.80 | 3.44 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $537.71M | 3.46 | 4.63 | 6.00 | 6.13 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $537.59M | 1.87 | 2.92 | 5.55 | 6.22 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $541.49M | 5.42 | 12.18 | 12.18 | 12.18 |
| Delcath Systems, Inc. (DCTH)vs › | $536.81M | 8.95 | 10.43 | 5.97 | 5.34 |
| Shattuck Labs, Inc. (STTK)vs › | $543.14M | 27.59 | 10.29 | 10.12 | 12.12 |
| ProKidney Corp. (PROK)vs › | $535.96M | 8.36 | 10.03 | 20.35 | 14.11 |
| Monopar Therapeutics Inc. (MNPR)vs › | $525.68M | 33.56 | 31.41 | 17.80 | 16.41 |
| Immix Biopharma, Inc. (IMMX)vs › | $525.57M | 25.13 | 6.17 | 7.34 | 19.91 |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
Quick Ratio
1.68
Excludes inventory
Current Ratio
1.68
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 1.68 |
| 2026-03-31 | 2.27 |
| 2025-12-31 | 2.38 |
| 2025-09-30 | 3.07 |
| 2025-06-30 | 2.66 |
| 2025-03-31 | 3.28 |
| 2024-12-31 | 2.09 |
| 2024-09-30 | 2.74 |
| 2024-06-30 | 3.17 |
| 2024-03-31 | 3.46 |
| 2023-12-31 | 2.75 |
| 2023-09-30 | 3.99 |
| 2023-06-30 | 5.41 |
| 2023-03-31 | 4.12 |
| 2022-12-31 | 3.30 |
| 2022-09-30 | 5.54 |
| 2022-06-30 | 5.20 |
| 2022-03-31 | 5.76 |
| 2021-12-31 | 2.41 |
| 2021-09-30 | 13.76 |
| 2021-06-30 | 18.54 |
| 2021-03-31 | 0.00 |
